# Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

> **NCT06718244** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** single dose of Inaticabtagene autoleucel

## Key facts

- **NCT ID:** NCT06718244
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-10
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06718244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06718244, "Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT06718244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*